A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy

Background: Hypertriglyceridaemia is a recognised metabolic abnormality in HIV-infected people, increasing in severity in people treated with highly active antiretroviral therapy (HAART). An alternative treatment for hypertriglyceridaemia in non-HIV-infected populations is omega-3 fatty acid supplementation. This study aimed to compare the effectiveness of omega-3 fatty acid supplementation and placebo in lowering fasting triglyceride levels in HIV-infected patients on HAART. Methods: A placebo-controlled, randomised, double-blind trial in participants on stable HAART with fasting triglycerides of >3.5 mm to 10.0 mm using 9 g of omega-3 fatty acids versus placebo (olive oil) after a 6-week lead in on dietary therapy. Results: Eleven patients were enrolled. The mean triglyceride level for the population decreased from 5.02 mm at baseline to 4.44 mm (–11.6%) after dietary intervention and 3.37 mm (–32.9%) after the 8-week treatment period. In the omega-3 fatty acid arm of the study, triglycerides fell from 5.34 mm to 5.02 mm (–6%) after dietary intervention and to 2.30 mm (–56.9%) after the treatment period. In the placebo arm of the study, triglycerides fell from 4.77 mm to 4.05 mm (–15.1%) after dietary intervention and to 4.08 mm (–14.5%) after the treatment period. Using the random effects model, a statistically significant effect on triglycerides of omega-3 fatty acid versus placebo was found (χ2 = 6.04, P = 0.0487). The estimated difference between groups for change in mean triglycerides over 8 weeks was –2.32 mm (95% CI –4.52, –0.12 mm). Conclusions: Omega-3 fatty acids are likely to be an effective treatment for hypertriglyceridaemia in HIV-infected males on HAART.

Download Full-text

Maternal omega-3 fatty acid supplementation on vitamin B12 rich diet improves brain omega-3 fatty acids, neurotrophins and cognition in the Wistar rat offspring

Brain and Development ◽

10.1016/j.braindev.2013.12.007 ◽

2014 ◽

Vol 36 (10) ◽

pp. 853-863 ◽

Cited By ~ 22

Author(s):

Richa Rathod ◽

Amrita Khaire ◽

Nisha Kemse ◽

Anvita Kale ◽

Sadhana Joshi

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Vitamin B12 ◽

Wistar Rat ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Fatty Acid Supplementation ◽

Acid Supplementation ◽

Omega 3 Fatty Acid ◽

Rat Offspring

Download Full-text

Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis

Journal of International Medical Research ◽

10.1177/0300060520953684 ◽

2020 ◽

Vol 48 (12) ◽

pp. 030006052095368

Author(s):

Chenyang Wang ◽

Dong Han ◽

Xiaojing Feng ◽

Jing Wu

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Meta Analysis ◽

Cochrane Library ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Gastrointestinal Dysfunction ◽

Fatty Acid Supplementation ◽

Acid Supplementation ◽

Omega 3 Fatty Acid

Objectives The efficacy of omega-3 fatty acids in the treatment of sepsis is controversial. We conducted an updated meta-analysis to clarify the efficacy of omega-3 fatty acids in patients with sepsis. Methods PubMed, EMBASE, and the Cochrane Library were searched for randomized clinical trials (RCTs) on omega-3 fatty acid supplementation in adults with sepsis. Results Twenty eligible RCTs involving 1514 patients were included in the meta-analysis. Omega-3 fatty acid supplementation was linked to reductions of mortality ( I2 = 0, relative risk [RR] = 0.82, 95% confidence interval [CI] = 0.69–0.97), the duration of mechanical ventilation (DMV; I2 = 74%, weighted mean difference [WMD] = −2.20, 95% CI = −4.00 to −0.40), and intensive care unit (ICU) length of stay (LOS; I2 = 91%, WMD = −3.86, 95% CI = −5.72 to −2.01). Subgroup analysis illustrated that mortality was significantly reduced in patients with sepsis and gastrointestinal dysfunction (RR = 0.5, 95% CI = 0.29–0.86, I2 = 0). Conclusion Omega-3 fatty acid supplementation might be associated with reduced mortality in patients with sepsis, especially those with gastrointestinal dysfunction. Furthermore, omega-3 fatty acid administration could shorten DMV and ICU LOS.

Download Full-text

Resolution of a therapy-resistant focal atrial tachycardia after omega-3 fatty acid supplementation

Cardiology in the Young ◽

10.1017/s1047951119001069 ◽

2019 ◽

Vol 29 (7) ◽

pp. 989-992 ◽

Cited By ~ 1

Author(s):

Reiner Buchhorn ◽

Christian Willaschek

Keyword(s):

Fatty Acid ◽

Atrial Tachycardia ◽

Antiarrhythmic Effect ◽

Autonomous Nervous System ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Fatty Acid Supplementation ◽

Acid Supplementation ◽

Omega 3 Fatty Acid ◽

Focal Atrial Tachycardia

AbstractWe report on a 14-year-old boy with focal atrial tachycardia. After failure of catheter ablation and medical therapy he received 2 g omega-3 fatty acid supplementation while waiting on repeat ablation. Focal atrial tachycardia disappeared 4 weeks later and antiarrhythmic therapy was terminated. We discuss the antiarrhythmic effect of omega 3-fatty acids on the autonomous nervous system based upon six 24-hour Holter electrocardiographs.

Download Full-text

Review of Omega-3 Fatty Acids for the Treatment of Attention Deficit/Hyperactivity Disorder

Health Services Insights ◽

10.4137/hsi.s3614 ◽

2009 ◽

Vol 2 ◽

pp. HSI.S3614

Author(s):

Jamie N. Brown ◽

Nicole Panosh

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Attention Deficit ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Fatty Acid Supplementation ◽

Acid Supplementation ◽

Omega 3 Fatty Acid ◽

Hyperactivity Disorder ◽

Clinically Significant

Objective To review the efficacy of omega-3 fatty acids in the treatment of attention deficit/hyperactivity disorder (ADHD). Data Souces Literature was accessed via MEDLINE (1950–February 2009) and International Pharmaceutical Abstracts (1960–2009) using the medical subject heading terms omega-3 fatty acids and attention deficit disorder with hyperactivity. Additional references were found by searching bibliographic references of resulting citations. Study Selection and Data Extraction All English-language, placebo controlled publications identified were analyzed for significance. Studies relevant to the objective were used, including eight studies evaluating the use of omega-3 fatty acid in the treatment of children with symptoms of ADHD. Data Synthesis Omega-3 fatty acid supplementation has been found to have variable efficacy in the treatment of patients with ADHD. Of the eight studies evaluated, three demonstrated no significant improvements in any evaluation criteria, with five studies reporting positive effects in at least one outcome measure. All positive efficacy studies included concomitant supplementation with omega-6 fatty acids. No clinically significant adverse effects were identified in the reviewed studies. Conclusions Based on the available data, current fatty acid supplementation techniques do not appear to be a consistant method of controlling ADHD symptoms. Without better evidence to determine the true value of fatty acids in the treatment of ADHD, omega-3 fatty acid use should be isolated to adjuvant supplementation or used in patients unable or unwilling to take stimulant medications. If recommended, there does not appear to be clinically significant adverse events associated with omega-3 fatty acid supplementation and this would be a safe treatment modality.

Download Full-text